Hepatitis C
Cardiovascular Disease Risk Is Higher for People with Hepatitis C
- Details
- Category: HCV-Related Conditions
- Published on Thursday, 21 January 2016 00:00
People with hepatitis C are at higher risk of dying from cardiovascular disease, having a stroke, or developing other cardiovascular problems than people with similar risk factors for heart disease who do not have hepatitis C, a meta-analysis of published studies has shown. The findings, published in the January 2016 edition of Gastroenterology, come from a meta-analysis of 22 epidemiological studies conducted in Italy.
AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 January 2016 00:00
An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.
Sofosbuvir/Daclatasvir Combination Could Be Produced for $200 per Hepatitis C Cure
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 15 December 2015 00:00
Month-by-month tracking of the prices paid in India for the chemicals used to make direct-acting antivirals to treat hepatitis C shows that it is now possible to make and sell a combination of drugs to cure hepatitis C virus (HCV) infection for less than $200, Andrew Hill of Liverpool University said at the Second European HIV Hepatitis Co-infection Conference in London last week.
New Drugs Could Halt U.S. Hepatitis C Epidemic, but Only with Increased Testing and Treatment
- Details
- Category: HCV Treatment
- Published on Sunday, 10 January 2016 00:00
Treatment using direct-acting antiviral agents (DAAs) could have a major impact on the hepatitis C virus (HCV) epidemic in the U.S., according to a model published in the November 30 online edition of Clinical Infectious Diseases. A 4-fold increase in treatment rates could prevent over a quarter of a million HCV-related deaths by 2040, and prevalence could be reduced by 90% with the scale up of screening efforts, especially targeting people who inject drugs (PWID). But the investigators caution that elimination of the epidemic with DAAs would require near-universal testing and a 20% annual treatment rate.
AASLD 2015: U.S. Faces Biggest Burden of Hepatitis C Treatment Costs Before 2020
- Details
- Category: HCV Treatment
- Published on Wednesday, 09 December 2015 00:00
The cost of treating hepatitis C is likely to decline dramatically over the next decade in the U.S., not because of cuts in drug prices, but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the AASLD Liver Meeting in San Francisco last month.
Hepatitis C Linked to Increased Risk of Parkinson's Disease, Studies Show
- Details
- Category: HCV-Related Conditions
- Published on Wednesday, 06 January 2016 00:00
People with hepatitis C virus (HCV) infection may be more likely to develop Parkinson's disease, especially when combined with other risk factors, though the reason for the association is not fully understood, according to a pair of recently published studies from Taiwan.
AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 December 2015 00:00
Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C coinfection, was well-tolerated, and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the 2015 AASLD Liver Meeting last month in San Francisco. These results confirm that HIV/HCV coinfected people respond as well to interferon-free therapy as those with HCV alone.
3. Better Options for Treating HCV Genotype 3 and Advanced Liver Disease
- Details
- Category: HCV Treatment
- Published on Wednesday, 30 December 2015 00:00
This year saw the emergence of new and better treatment options for people with hepatitis C virus (HCV) genotypes other than 1 and for those with advanced liver disease.
AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 25 November 2015 00:00
Hepatitis C patients who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir standard therapy, according to results from the SYNERGY study presented at the 2015 AASLD Liver Meeting last week in San Francisco. A related analysis showed that emergence of certain drug-resistance mutations was common during very short therapy, but this did not appear to compromise response to retreatment.
More Articles...
- AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks
- AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
- AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK
- AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
- AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
Web Design and Development by